Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Delcath Systems, Inc. (Nasdaq: DCTH), which is testing its proprietary treatment system for metastatic cancers to the liver, announced today that the U.S. Food and Drug Administration ("FDA") will allow the Company to initiate an Expanded Use – Intermediate Size Population protocol for the hepatic arterial infusion of melphalan with venous filtration via the Delcath PHP System™ for patients with ocular and cutaneous melanoma metastatic to the liver.

Expanded access programs make certain treatments still being evaluated in late-stage trials available to patients for whom no satisfactory alternatives are available. To grant expanded access, the FDA generally must be satisfied that the potential benefit for the patient justifies the potential risk.

Delcath recently announced that sufficient patient events had occurred in its randomized, multi-center Phase III trial of melphalan for data analysis to begin. Under the Expanded Access Program, the five centers treating the highest number of patients during the Phase III trial may continue to treat patients with metastatic melanoma to the liver while the data is being evaluated.  The Expanded Access Program allows patients to be enrolled into the non-randomized study, materially identical to the melphalan arm of the randomized Phase III trial that will be submitted to FDA for a New Drug Application ("NDA") review.  Patients treated under the Expanded Access Program will not be included in the data analysis currently underway.  Delcath is currently in the final stages of negotiating research contracts with the individual institutions and achieving Institutional Review Board ("IRB") approvals at these five centers.  The Company may in the future petition the FDA to add additional centers.

"The Expanded Access Program is terrific news," said Eamonn P. Hobbs, President and CEO of Delcath. "It allows us to offer help to patients with metastatic melanoma to the liver who have no other options at this stage of their disease.  And as it is based on available evidence, this development underscores our confidence in the efficacy of high-dose melphalan combined with the Delcath PHP System for this unmet medical need."

Delcath's Phase III trial completed enrollment of 93 patients in October 2009 and the 73rd event required under the study's Special Protocol Assessment prior to the initiation of patient data analysis, was reported on February 4, 2010.  The trial's data analysis has begun and involves the initial review by the trial's principal clinical investigators at each of the enrolling centers, additional review by the Company's retained Clinical Research Organization, and then a final review by an independent core lab for verification of results before final statistical results can be attained.  Given recently updated schedules by the external reviewers, the completion of this comprehensive review process is now expected to be in April and the Company plans to promptly release key elements as they become available.  Submission of the NDA package to the FDA for marketing approval will be made as soon as practically possible, once the data analysis process is completed.

"Our goal is to make sure that all data from the trial is thoroughly reviewed before any release and we fully support the comprehensive process underway.  We remain highly confident that the trial's data will meet the trial's primary endpoint, and our confidence has been further buoyed by the FDA's acknowledgement of an expanded access program," Mr. Hobbs concluded.